Risk of selected site-specific gastrointestinal cancers in patients with breast cancer (1990–2017), by follow-up periods
| +1 year* | 2–5 years | 6–10 years | +10 years | |||||||||
| O/E | IR per 100 000 PY (95% CI) | SIR (95% CI) | O/E | IR per 100 000 PY (95% CI) | SIR (95% CI) | O/E | IR per 100 000 PY (95% CI) | SIR (95% CI) | O/E | IR per 100 000 PY (95% CI) | SIR (95% CI) | |
| Gastrointestinal cancers overall | 2124/1931 | 319 (305 to 332) | 1.10 (1.05 to 1.15) | 667/660 | 249 (230 to 268) | 1.01 (0.94 to 1.09) | 709/605 | 336 (312 to 361) | 1.17 (1.09 to 1.26) | 748/666 | 398 (369 to 426) | 1.12 (1.04 to 1.21) |
| Upper gastrointestinal cancers | 279/222 | 42 (37 to 47) | 1.26 (1.11 to 1.41) | 89/78 | 33 (26 to 40) | 1.14 (0.92 to 1.41) | 101/70 | 48 (39 to 57) | 1.45 (1.18 to 1.76) | 89/75 | 47 (37 to 57) | 1.19 (0.96 to 1.47) |
| Oesophagus | 83/77 | 12 (10 to 15) | 1.07 (0.86 to 1.33) | 17/26 | 6 (3 to 9) | 0.64 (0.37 to 1.03) | 38/24 | 18 (12 to 24) | 1.55 (1.10 to 2.13) | 28/26 | 15 (9 to 20) | 1.06 (0.70 to 1.53) |
| Stomach | 157/115 | 24 (20 to 27) | 1.37 (1.16 to 1.60) | 61/41 | 23 (17 to 29) | 1.48 (1.13 to 1.90) | 51/36 | 24 (18 to 31) | 1.43 (1.06 to 1.88) | 45/38 | 24 (17 to 31) | 1.19 (0.87 to 1.60) |
| Small intestine | 39/30 | 6 (4 to 8) | 1.29 (0.92 to 1.76) | 11/10 | 4 (2 to 7) | 1.09 (0.54 to 1.94) | 12/9 | 6 (2 to 9) | 1.26 (0.65 to 2.21) | 16/11 | 9 (4 to 13) | 1.50 (0.86 to 2.44) |
| Lower gastrointestinal cancers | 1429/1301 | 214 (203 to 226) | 1.10 (1.04 to 1.16) | 453/442 | 169 (154 to 185) | 1.03 (0.93 to 1.12) | 476/407 | 226 (206 to 246) | 1.17 (1.07 to 1.28) | 500/452 | 266 (242 to 289) | 1.11 (1.01 to 1.21) |
| Colon incl. rectosigmoid colon | 1028/916 | 154 (145 to 164) | 1.12 (1.06 to 1.19) | 314/307 | 117 (104 to 130) | 1.02 (0.91 to 1.14) | 342/286 | 162 (145 to 179) | 1.20 (1.07 to 1.33) | 372/323 | 198 (178 to 218) | 1.15 (1.04 to 1.28) |
| Rectum | 362/343 | 54 (49 to 60) | 1.06 (0.95 to 1.17) | 128/120 | 48 (40 to 56) | 1.07 (0.89 to 1.27) | 121/108 | 57 (47 to 68) | 1.12 (0.93 to 1.34) | 113/115 | 60 (49 to 71) | 0.98 (0.81 to 1.18) |
| Anal canal | 39/42 | 6 (4 to 8) | 0.93 (0.66 to 1.27) | 11/15 | 4 (2 to 7) | 0.73 (0.36 to 1.31) | 13/13 | 6 (3 to 10) | 0.98 (0.52 to 1.67) | 15/14 | 8 (4 to 12) | 1.11 (0.62 to 1.83) |
| Other gastrointestinal cancers | 416/408 | 62 (56 to 68) | 1.02 (0.92 to 1.12) | 125/140 | 47 (39 to 55) | 0.89 (0.74 to 1.06) | 132/128 | 63 (52 to 73) | 1.03 (0.86 to 1.22) | 159/140 | 84 (71 to 98) | 1.13 (0.97 to 1.33) |
| Liver | 47/64 | 7 (5 to 9) | 0.73 (0.54 to 0.97) | 13/22 | 5 (2 to 8) | 0.58 (0.31 to 1.00) | 19/20 | 9 (5 to 13) | 0.95 (0.57 to 1.48) | 15/22 | 8 (4 to 12) | 0.69 (0.38 to 1.13) |
| Gallbladder and biliary tract | 65/68 | 10 (7 to 12) | 0.96 (0.74 to 1.23) | 20/24 | 7 (4 to 11) | 0.85 (0.52 to 1.31) | 16/21 | 8 (4 to 11) | 0.76 (0.43 to 1.23) | 29/23 | 15 (10 to 21) | 1.26 (0.85 to 1.82) |
| Pancreas | 304/277 | 46 (40 to 51) | 1.10 (0.98 to 1.23) | 92/94 | 34 (27 to 41) | 0.97 (0.79 to 1.20) | 97/87 | 46 (37 to 55) | 1.12 (0.91 to 1.36) | 115/95 | 61 (50 to 72) | 1.21 (1.00 to 1.45) |
*Main analysis
E, expected; IR, incidence rate; O, observed; PY, person years; SIR, standardised incidence ratio.